Monod Bio Licenses Protein Technologies to SignalChem Biotech

August 26, 2026
Monod Bio and SignalChem Biotech signed a nonexclusive license for LuxSit luciferase technology and NovoBodies for custom luminescent assays and protein fusion services.

Monod Bio and SignalChem Biotech announced in a press release a licensing agreement for Monod Bio's LuxSit luciferase technology and NovoBodies.

The agreement is not exclusive. SignalChem Biotech may use the technologies in custom luminescent assays and protein fusion services for research customers.

LuxSit is a luciferase designed with AI for use in luminescent biosensors. NovoBodies are compact binding proteins designed for target recognition.

SignalChem Biotech is a wholly owned subsidiary of Sino Biological. The companies did not disclose financial terms.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Enterprise AI Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Enterprise

08/26
PENTAX Medical Expands MAGENTIQ EYE Colonoscopy AI Partnership Worldwide
08/26
Outperform Institute and SkyGeni Partner on AI Revenue Risk Offering
08/26
Ontic Adds Seerist Risk Intelligence to Security Platform
08/26
Blend360 Expands AI Services Into Brazil
08/26
Oliver AI Raises Early Funding for OliverDB Agentic AI Data Platform

More from: Life Sciences

08/26
PENTAX Medical Expands MAGENTIQ EYE Colonoscopy AI Partnership Worldwide
08/26
PrecisionLife Selects Gencove for US DNA Wellness Reports
08/26
Arintra Raises $25 Million for Healthcare Revenue Assurance AI
08/26
Onos Health Raises $17 Million for Behavioral Health AI Platform
08/26
Knack Launches HIPAA Compliant MCP Server for AI App Builders

Subscribe to Enterprise AI Brief

Weekly report on AI business applications, enterprise software releases, automation tools, and industry implementations.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like